Skip to main content
Fig. 1 | Stem Cell Research & Therapy

Fig. 1

From: Standard toxicity study of clinical-grade allogeneic human bone marrow-derived clonal mesenchymal stromal cells

Fig. 1

The overall program for injection of BM-cMSCs. A Injections were performed by two different routes in the treatment and control groups. In the IVD injection route, 2.5 × 106 cells were suspended in NS mixed with an equal volume of HA. In the IV injection route, 6 × 106 cells/kg body weight in 500 μl NS were injected in the treatment group and 500 μl NS in the control group. The animals were followed for 14 days (subacute) and 90 days (subchronic). At the end of the subacute and subchronic phases, the animals were euthanized and their tissues were processed for hematological and biochemistry laboratory assessments, and histopathology analysis. For each administration route, we used 48 Sprague Dawley (SD) rats of both sexes (n = 24 female; n = 24 male). B The schematic of surgery and method of cell injection into the disc is shown. For IV injection route, cells were injected in the tail vein. For IVD injection route, laminectomy was performed on the dorsal region to expose the lumbar spine. The injection was performed on disc located between the L4 and L5 vertebrae by a 21G needle. After injection, the surgical wounds were closed routinely. BM-cMSCs: bone marrow-derived clonal MSCs; IVD: intervertebral disc; NS: normal saline; HA: hyaluronic acid; IV: intravenous

Back to article page